{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T09:36:14Z","timestamp":1793871374662,"version":"4.6.1"},"reference-count":30,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Joint Bone Spine"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1016\/j.jbspin.2015.07.011","type":"journal-article","created":{"date-parts":[[2015,12,19]],"date-time":"2015-12-19T08:42:38Z","timestamp":1450514558000},"page":"314-317","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":57,"title":["Risk of cutaneous adverse events with febuxostat treatment in patients with skin reaction to allopurinol. A retrospective, hospital-based study of 101 patients with consecutive allopurinol and febuxostat treatment"],"prefix":"10.1016","volume":"83","author":[{"given":"Thomas","family":"Bardin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0384-8587","authenticated-orcid":false,"given":"G\u00e9rard","family":"Chal\u00e8s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tristan","family":"Pascart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e9-Marc","family":"Flipo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang","family":"Korng Ea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Claude","family":"Roujeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lie","family":"Delayen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Clerson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jbspin.2015.07.011_bib0155","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1136\/ard.2006.055269","article-title":"EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies including Therapeutics (ESCISIT)","volume":"65","author":"Zhang","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2015.07.011_bib0160","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/acr.21772","article-title":"2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia","volume":"64","author":"Khanna","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.jbspin.2015.07.011_bib0165","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1136\/ard.2008.091462","article-title":"A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300\u2013600mg\/day versus benzbromarone 100\u2013200mg\/day in patients with gout","volume":"68","author":"Reinders","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2015.07.011_bib0170","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/j.1525-139X.2007.00270.x","article-title":"Allopurinol dosing in renal impairment: walking the tightrope between adequate urate lowering and adverse events","volume":"20","author":"Dalbeth","year":"2007","journal-title":"Semin Dial"},{"key":"10.1016\/j.jbspin.2015.07.011_bib0175","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1002\/acr.21817","article-title":"Severe cutaneous reactions requiring hospitalization in allopurinol initiators: a population-based cohort study","volume":"65","author":"Kim","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.jbspin.2015.07.011_bib0180","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/sj.jid.5701033","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study","volume":"128","author":"Mockenhaupt","year":"2008","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jbspin.2015.07.011_bib0185","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1002\/art.34488","article-title":"Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol","volume":"64","author":"Stamp","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2015.07.011_bib0190","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0002-9343(84)90743-5","article-title":"Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency","volume":"76","author":"Hande","year":"1984","journal-title":"Am J Med"},{"key":"10.1016\/j.jbspin.2015.07.011_bib0195","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1136\/ard.40.3.245","article-title":"Acute adverse reactions attributed to allopurinol in hospitalised patients","volume":"40","author":"McInnes","year":"1981","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2015.07.011_bib0200","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1056\/NEJM198705073161913","article-title":"Occurrence of exanthema in relation to aminopenicillin preparations and allopurinol","volume":"316","author":"Hoigne","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jbspin.2015.07.011_bib0205","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1177\/0091270012439715","article-title":"Clinical risk factors for adverse events in allopurinol users","volume":"53","author":"Ryu","year":"2012","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.jbspin.2015.07.011_bib0210","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1002\/art.24209","article-title":"Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial","volume":"59","author":"Schumacher","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2015.07.011_bib0215","doi-asserted-by":"crossref","first-page":"R63","DOI":"10.1186\/ar2978","article-title":"The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial","volume":"12","author":"Becker","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jbspin.2015.07.011_bib0220","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1056\/NEJMoa050373","article-title":"Febuxostat compared with allopurinol in patients with hyperuricemia and gout","volume":"353","author":"Becker","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jbspin.2015.07.011_bib0225","unstructured":"Registration file, MIOL Febuxostat Risk Management plan v.4.1, 25 Oct 2013."},{"key":"10.1016\/j.jbspin.2015.07.011_bib0230","first-page":"S504","article-title":"Cross-sensitivity of allopurinol and febuxostat-induced drug rash with eosinophilia and systemic symptoms (DRESS) syndrome","volume":"25","author":"Mauck","year":"2010","journal-title":"J Gen Intern Med"},{"key":"10.1016\/j.jbspin.2015.07.011_bib0235","doi-asserted-by":"crossref","first-page":"659","DOI":"10.3899\/jrheum.111161","article-title":"Febuxostat hypersensitivity","volume":"39","author":"Abeles","year":"2012","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jbspin.2015.07.011_bib0240","unstructured":"ANSM. Lettre aux professionels de sant\u00e9 sur le risque de survenue de r\u00e9actions d\u2019hypersensibilit\u00e9 grave, incluant le syndrome de Stevens-Johnson et des chocs anaphylactiques aigus lors de la prise d\u2019ad\u00e9nuric(r) (f\u00e9buxostat) (15\/6\/2012). http:\/\/.ansm.sante.fr\/S-informer\/informations-de-securite-Lettres-aux-professionnels-de-sante\/Adenuric-R-febuxostat-Risque-de-survenue-de-reaction-d-hypersensibilite-grave-incluant-le-syndrome-de-Stevens-Johnson-et-des-chocs-anaphylactiques-aigus-Lettre-aux-professionnels-de-sante."},{"key":"10.1016\/j.jbspin.2015.07.011_bib0245","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1002\/art.1780200320","article-title":"Preliminary criteria for the classification of the acute arthritis of primary gout","volume":"20","author":"Wallace","year":"1977","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2015.07.011_bib0250","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1080\/10543406.2011.607736","article-title":"The bootstrap and Markov-chain Monte Carlo","volume":"21","author":"Efron","year":"2011","journal-title":"J Biopharm Stat"},{"key":"10.1016\/j.jbspin.2015.07.011_bib0255","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1136\/annrheumdis-2013-203779","article-title":"Revisiting comorbidities in gout: a cluster analysis","volume":"74","author":"Richette","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2015.07.011_bib0260","first-page":"S68","article-title":"Gouty patients with history of adverse reaction to allopurinol are not at higher risk of reaction to febuxostat (abstract)","volume":"66","author":"Bardin","year":"2014","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2015.07.011_bib0265","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.3899\/jrheum.110092","article-title":"Safety and efficacy of febuxostat treatment in subjects with gout and severe allopurinol adverse reactions","volume":"38","author":"Chohan","year":"2011","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jbspin.2015.07.011_bib0270","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.tox.2004.12.022","article-title":"Clinical heterogeneity of drug hypersensitivity","volume":"209","author":"Roujeau","year":"2005","journal-title":"Toxicology"},{"key":"10.1016\/j.jbspin.2015.07.011_bib0275","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1172\/JCI113798","article-title":"Anticonvulsant hypersensitivity syndrome. In vitro assessment of risk","volume":"82","author":"Shear","year":"1988","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jbspin.2015.07.011_bib0280","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1017\/S0317167100021880","article-title":"Cross sensitivity of skin rashes with antiepileptic drugs","volume":"24","author":"Hyson","year":"1997","journal-title":"Can J Neurol Sci"},{"key":"10.1016\/j.jbspin.2015.07.011_bib0285","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1212\/01.wnl.0000334295.50403.4c","article-title":"Cross-sensitivity of skin rashes with antiepileptic drug use","volume":"71","author":"Hirsch","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.jbspin.2015.07.011_bib0290","doi-asserted-by":"crossref","DOI":"10.1016\/j.amjmed.2005.10.052","article-title":"Is there cross-reactivity between penicillins and cephalosporins?","volume":"119","author":"Apter","year":"2006","journal-title":"Am J Med"},{"key":"10.1016\/j.jbspin.2015.07.011_bib0295","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1056\/NEJMoa022963","article-title":"Absence of cross-reactivity between sulfonamide antibiotics and sulfonamide nonantibiotics","volume":"349","author":"Strom","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jbspin.2015.07.011_bib0300","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1002\/j.1552-4604.1981.tb01749.x","article-title":"Potentiation of ampicillin skin reactions by allopurinol or hyperuricemia","volume":"21","author":"Jick","year":"1981","journal-title":"J Clin Pharmacol"}],"container-title":["Joint Bone Spine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X15002882?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X15002882?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,16]],"date-time":"2018-09-16T15:50:58Z","timestamp":1537113058000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1297319X15002882"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,5]]}},"alternative-id":["S1297319X15002882"],"URL":"https:\/\/doi.org\/10.1016\/j.jbspin.2015.07.011","relation":{},"ISSN":["1297-319X"],"issn-type":[{"value":"1297-319X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk of cutaneous adverse events with febuxostat treatment in patients with skin reaction to allopurinol. A retrospective, hospital-based study of 101 patients with consecutive allopurinol and febuxostat treatment","name":"articletitle","label":"Article Title"},{"value":"Joint Bone Spine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbspin.2015.07.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Published by Elsevier Masson SAS on behalf of Soci\u00e9t\u00e9 fran\u00e7aise de rhumatologie.","name":"copyright","label":"Copyright"}]}}